% | $
Quotes you view appear here for quick access.

Sangamo Biosciences Inc. Message Board

  • jbpdli jbpdli Mar 20, 2013 1:02 PM Flag

    maybe BMSN and SGMO should get in bed together

    BMSN going to give DNDN something to think about:

    Provenge is a vaccine for prostate cancer that costs $93,000 per treatment cycle1 and had sales of $240 million in the last three quarters of 2012, despite only increasing survival by 4.1 months2. Dendreon's Provenge requires extraction of dendritic cells, a "master cell" of the immune system, and manipulation outside of the body. The technology developed by Professor Min involves "training" of the same dendritic cells inside of the body by administration of specific nanoparticles. Proof of concept of these nanoparticles were published by Professor Min in collaboration with University of California San Diego in the prestigious scientific journal Blood (Zheng et al. Blood. 2009 Mar 19;113(12):2646-54).

5.66-0.31(-5.19%)Feb 5 4:00 PMEST